Changes in levels of immune activation and reconstitution markers among HIV-1-infected Africans receiving antiretroviral therapy.
OBJECTIVE
To describe changes in immune activation and reconstitution markers among HIV-1-infected patients receiving antiretroviral therapy (ART) in Abidjan, Côte d'Ivoire.


METHODS
Between November 1998 and February 2001, we analyzed changes in immune activation and reconstitution markers among 52 patients. Good virologic responders (n = 26) were defined as those who had suppressed and maintained plasma viral load (VL) below the detection limit of the assay for at least 12 months. Poor virologic responders (n = 26) were defined as those with a detectable VL at 6 and 12 months after beginning ART.


RESULTS
Of the 26 good virologic responders, 20 (77%) were on highly active antiretroviral therapy (HAART) compared with one (4%) of the poor responders. Among the 26 good responders, baseline median levels of CD38+CD8+ T cells were elevated, but had decreased significantly at 6 months (P < 0.001) and at 12 months of therapy (P < 0.001). Median levels of HLA-DR+CD8+ T cells also decreased from baseline at 6 months (P < 0.001) and at 12 months of therapy (P < 0.001). Levels of CD62L+CD4+ T cells increased steadily during the 6 and 12 months of therapy and reached levels observed among HIV-negative blood donors (P = 0.07). Among the 26 poor responders, median levels of CD38+CD8+ T cells decreased significantly at 12 months of therapy (P = 0.006), but were higher than levels in blood donors (P = 0.005). Levels of HLA-DR+CD8+ T cells decreased significantly at 12 months of therapy (P < 0.001). Levels of CD62L+CD4+ decreased over time.


CONCLUSIONS
Our results suggest that HAART can be successfully used in African populations with elevated baseline immune activation markers.
Koblavi-Dème
Stéphania
S
Projet RETRO-CI, Abidjan, Côte d'Ivoire.
Maran
Matthieu
M
Kabran
Nguessan
N
Borget
Marie Yolande
MY
Kalou
Mireille
M
Kestens
Luc
L
Maurice
Chantal
C
Sassan-Morokro
Madeleine
M
Ekpini
Ehounou R
ER
Roels
Thierry H
TH
Chorba
Terence
T
Nkengasong
John N
JN
D036541:ADP-ribosyl Cyclase / Q000097:blood; D051997:ADP-ribosyl Cyclase 1; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D015703:Antigens, CD / Q000097:blood; D023241:Antiretroviral Therapy, Highly Active; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D007560:Cote d'Ivoire; D003906:Developing Countries; D005500:Follow-Up Studies; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology* / Q000821:virology; D015497:HIV-1; D006684:HLA-DR Antigens / Q000097:blood; D006801:Humans; D008562:Membrane Glycoproteins; D016176:T-Lymphocyte Subsets / Q000276:immunology; D016896:Treatment Outcome; D019562:Viral Load
D019380:Anti-HIV Agents; D015703:Antigens, CD; D006684:HLA-DR Antigens; D008562:Membrane Glycoproteins; D036541:ADP-ribosyl Cyclase; C498154:CD38 protein, human; D051997:ADP-ribosyl Cyclase 1